Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

48.27
+0.44000.92%
Post-market: 48.400.1328+0.28%19:42 EST
Volume:4.79M
Turnover:230.03M
Market Cap:116.57B
PE:12.84
High:48.45
Open:47.83
Low:47.66
Close:47.83
52wk High:60.12
52wk Low:44.62
Shares:2.42B
Float Shares:2.20B
Volume Ratio:1.06
T/O Rate:0.22%
Dividend:2.27
Dividend Rate:4.71%
EPS(TTM):3.76
EPS(LYR):3.76
ROE:6.66%
ROA:4.56%
PB:1.37
PE(LYR):12.84

Loading ...

Sanofi Obtains FDA Breakthrough Therapy Designation for Anemia Treatment

MT Newswires Live
·
Yesterday

OneSpaWorld to replace Dynavax in S&P 600 at open on 2/10

TIPRANKS
·
Feb 05

Sanofi's Rezurock Expands Provincial Access in Canada

MT Newswires Live
·
Feb 04

Sanofi Launches $1.18 Billion Share Buyback Program

MT Newswires Live
·
Feb 03

“Signal of Strength”: Sanofi (SNY) Launches €1 Billion Stock Buyback for 2026

TIPRANKS
·
Feb 03

Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says

MT Newswires Live
·
Feb 03

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Precious Metals Downturn

MT Newswires Live
·
Feb 02

Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code

MT Newswires Live
·
Feb 02

Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials

Benzinga_recent_news
·
Feb 02

Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease

MT Newswires Live
·
Feb 02

European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week

MT Newswires Live
·
Jan 31

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Benzinga
·
Jan 30

Sanofi Says EU Conditional Approval Recommended for Rezurock in Graft-versus-Host Disease

MT Newswires Live
·
Jan 30

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 30

Sector Update: Health Care

MT Newswires Live
·
Jan 29

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Dow Jones
·
Jan 29

Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks

Benzinga
·
Jan 29

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

Dow Jones
·
Jan 29

Sanofi Eyes High Single-Digit Sales Growth in 2026, Dupixent Patent Expiry Looms

Reuters
·
Jan 29

Star Drug Dupixent Hits Record Sales! Sanofi (SNY.US) Q4 Profit Exceeds Expectations

Stock News
·
Jan 29